RHÖN-KLINIKUM AG | 04/30/2014

Press Conference in Frankfurt am Main on 30 April 2014

Annual Result for 2013

  • Number of treated patients rises by 3.9 %
  • Financial figures significantly influenced by extraordinary effects
  • Revenue increases by 5.2 % and crosses the three billion mark for the first time
  • EBITDA falls slightly by 5.7 %
  • Net consolidated profit close to last year's level

Conclusion of Sale Transaction and Distribution of Proceeds, Status of Particle Therapy in Marburg

  • Transfer of 39 of the 40 hospitals sold to Fresenius / Helios
  • 95 % of the transaction volume realised by 28 February 2014
  • Proposal for dividend and share buy-back of up to roughly € 1.67 billion
  • Key points defined for purchase and operation of particle therapy unit in Marburg

In financial year 2013 a total of roughly 2.65 million patients were treated in the 54 RHÖN KLINIKUM AG hospitals which belonged to the corporate group last year. The number of patients treated thus increased by 3.9 % in comparison with the previous year. The revenue of the entire corporate group grew by 5.2 % and with € 3.01 billion crossed the three billion mark for the first time. Due to considerable extraordinary burdens from the transaction – structural one-off effects, consultation fees and costs for the necessary adjustment in staff in Bad Neustadt – earnings before interest, taxes, depreciation and amortisation was reduced by 5.7 %, now amounting to € 275.4 million following € 292.0 million for the previous year. Net consolidated profit remained almost unchanged at € 90.0 million, down by just 2.6 %.

"The transaction already initiated in the previous financial year placed considerable burdens on the company and tied resources. The achieved earnings are generally acceptable against this background," said Dr. Dr. Martin Siebert, CEO of RHÖN KLINIKUM AG.

Dividend and Method of Distributing the Proceeds from the Transaction with Fresenius/HELIOS
The Board of Management and Supervisory Board shall on the one hand propose to this year's ordinary Annual General Meeting on 12 June 2014 the distribution of a dividend totalling roughly € 34.6 million or € 0.25 per share as in the previous year. The Board of Management and Supervisory Board shall also propose to the AGM to distribute to the shareholders up to roughly € 1.67 billion from the proceeds of the transaction with Fresenius/HELIOS by way of share buy-back. The shares which are repurchased will be cancelled and the registered share capital reduced accordingly. The smaller corporate size will thus be taken into account. The share buy-back also enables shareholders to exit the company in a manner that limits the impact on the share price.

The offer price for the share buy-back shall be determined with the resolution on the documentation for the public purchase offer. The reference price for the lower limit amounts to € 23.54 and is based on the average share price on the Frankfurt stock exchange during the last three trading days immediately preceding 29 April 2014. The offer price may not be more than 7 % above this reference price. In the event that the share buy-back does not take place within certain time periods, an additional dividend in the amount of € 12.08 per share will be distributed. All the details of the resolutions proposed to the AGM are fully described in the invitation to the ordinary 2014 Annual General Meeting.

Employment in 2013

As of 31 December 2013 the RHÖN-KLINIKUM AG employed 43,363 employees, 304 more than in the previous year, at 54 hospitals in ten federal states. The hospitals of the company were some of the largest employers in many regions.

Status of the Particle Therapy at the Marburg Site

Contractual key points for the purchase and operation of the particle therapy unit as well as a concept of use at the university hospital in Marburg have now been defined following intensive negotiations with the federal state of Hesse, Siemens AG as the owner of the plant and the university hospital in Heidelberg. It is intended to incorporate these key points in specific agreements in the next few weeks. A joint company in the form of "Marburger Ionenstrahl-Therapiezentrum GmbH (MIT GmbH)“ (Marburg Ion Beam Therapy Centre) has been established with the university hospital in Heidelberg in order to ensure the long-term operation of the particle therapy unit. After the conclusion of the negotiations and the subsequent process of putting the unit into operation we shall be able to treat the first patients in 2015 with this worldwide leading facility for cancer therapy.

Outlook for 2014

RHÖN-KLINIKUM AG is refraining from giving a target for revenues and earnings for the current financial year 2014. The prime reasons for this are the unfinished structural changes in the company and the extraordinary effects which are caused by the sale and included in the balance sheet and which still have to be dealt with.

The company expects revenues of € 1.06 billion to € 1.12 billion and earnings before interest, tax, depreciation and amortisation (EBITDA) of between € 145 million and € 155 million for 2015, the first full financial year with the new corporate structure. This outlook is subject to any regulatory changes which may affect reimbursement rates in the coming year.

"2013 was a historic financial year for us due to the sale transaction," said Dr. Dr. Siebert. "RHÖN-KLINIKUM AG is now changing from a miscellaneous network of different hospitals to an integrated healthcare group with a clear focus on supplying high-class medical care in every respect. We offer our patients innovative maximum-care medical services. The already initiated creation of a medical network with various service providers will further strengthen the growth potential associated with the strategic re-orientation."